SHL Telemedicine files pre-submission with FDA for Over the Counter clearance of SHL'sSmartHeart™ full 12 Lead ECG

Tel Aviv/Zurich, 12 January 2021 - SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today that it has filed a pre-submission with the US Food and Drug Administration (FDA) for Over the Counter (OTC) use of its SmartHeart™ full 12 Lead ECG. SmartHeart™ is already FDA cleared and marketed in the US as a "prescription only" device.

The FDA's Pre-Submission Program (Pre-Sub) allows medical device manufacturers to discuss specific aspects of the regulatory process and requirements with the FDA. In the submission SHL requested a meeting with the FDA to discuss the agency's feedback on the proposed use of SmartHeart™ as OTC device and to determine the appropriate regulatory path.

"In the US alone, there are currently about 6.2 million annual visits to Emergency Departments due to chest pain and related symptoms - the second most common cause of visits, out of which 70% are unnecessary." said Erez Nachtomy, CEO of SHL Telemedicine. "With Over the Counter (OTC) clearance for use of SHL's unique and patented SmartHeart™, for performing full 12 Lead ECG, anytime and from anywhere, SmartHeart™ can be marketed directly to consumers to provide peace of mind and address the unmet need for remote cardiac care, representing an exceptional growth opportunity for SHL in the US market."

For further information please contact:

Martin Meier-Pfister, IRF, Phone: +41 43 244 81 40, shl@irf-reputation.ch


Press release (PDF)



Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50